Filing Details

Accession Number:
0001209191-20-045921
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2020-08-10 16:03:09
Reporting Period:
2020-08-05
Accepted Time:
2020-08-10 16:03:09
Original Submission Date:
2020-08-07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1645460 Cue Biopharma Inc. CUE Pharmaceutical Preparations (2834) 473324577
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1724870 Colin Sandercock 21 Erie Street
Cambridge MA 02139
Svp, General Counsel And Sec No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-05 13,374 $7.50 30,499 No 4 M Direct
Common Stock Disposition 2020-08-05 13,374 $20.00 17,125 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-08-05 13,374 $0.00 13,374 $7.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
130,000 2024-12-27 No 4 M Direct
Footnotes
  1. This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the "Original Form 4") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  4. These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018.